Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Utilization of MG-ADL in myasthenia gravis clinical research and care.
Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Muppidi S, et al. Among authors: silvestri nj. Muscle Nerve. 2022 Jun;65(6):630-639. doi: 10.1002/mus.27476. Epub 2022 Jan 6. Muscle Nerve. 2022. PMID: 34989427 Free PMC article. Review.
International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome.
Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, Harbo T, Hartung HP, Hughes RAC, Kusunoki S, van Doorn PA, Willison HJ; IGOS Consortium. Jacobs BC, et al. J Peripher Nerv Syst. 2017 Jun;22(2):68-76. doi: 10.1111/jns.12209. J Peripher Nerv Syst. 2017. PMID: 28406555 Free article.
Myasthenia gravis.
Silvestri NJ, Wolfe GI. Silvestri NJ, et al. Semin Neurol. 2012 Jul;32(3):215-26. doi: 10.1055/s-0032-1329200. Epub 2012 Nov 1. Semin Neurol. 2012. PMID: 23117946 Review.
Treatment-refractory myasthenia gravis.
Silvestri NJ, Wolfe GI. Silvestri NJ, et al. J Clin Neuromuscul Dis. 2014 Jun;15(4):167-78. doi: 10.1097/CND.0000000000000034. J Clin Neuromuscul Dis. 2014. PMID: 24872217 Review.
International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r.
Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, Bril V, Barnett C, Guptill JT, Sanders DB, Hobson-Webb L, Juel VC, Massey J, Gable KL, Silvestri NJ, Wolfe G, Cutter G, Nagane Y, Murai H, Masuda M, Farrugia ME, Carmichael C, Birnbaum S, Hogrel JY, Nafissi S, Fatehi F, Ou C, Liu W, Conaway M. Burns TM, et al. Among authors: silvestri nj. Muscle Nerve. 2016 Dec;54(6):1015-1022. doi: 10.1002/mus.25198. Epub 2016 Nov 7. Muscle Nerve. 2016. PMID: 27220659
Low-Dose Medication and Long-Term Outcome in Myasthenia Gravis.
Salins S, Teter B, Kavak K, Wolfe GI, Silvestri NJ. Salins S, et al. Among authors: silvestri nj. J Clin Neuromuscul Dis. 2016 Dec;18(2):61-66. doi: 10.1097/CND.0000000000000122. J Clin Neuromuscul Dis. 2016. PMID: 27861217
Rituximab in Treatment-Refractory Myasthenia Gravis.
Silvestri NJ, Wolfe GI. Silvestri NJ, et al. JAMA Neurol. 2017 Jan 1;74(1):21-23. doi: 10.1001/jamaneurol.2016.4367. JAMA Neurol. 2017. PMID: 27892981 No abstract available.
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
80 results